

ASX RELEASE | OSTEOPORE LIMITED

## Osteopore collaborates with Singular Health to validate patient-specific AI cranial implant design tool

### Highlights:

- *Binding MOU executed with Singular Health to validate their AI model and to conduct a comparative study between Osteopore's existing cranial implant design process and the new design process in a clinical environment.*
- *KickStart 2 grant to provide matched funding of an Artificial Intelligence (AI)-based program to automatically design replacement cranial implants.*
- *Osteopore believes that there are potentially significant design and process improvement opportunities using Singular Health's AI technology.*

**19 October 2021: Osteopore Limited** (ASX: OSX) ("Osteopore" or the "Company"), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants at commercial scale, is pleased to announce it has signed a binding memorandum of understanding (MOU) with Singular Health Group Ltd (ASX: SHG) ("Singular Health") to validate the results of their AI design-engine through a comparative study using a dataset provided by Osteopore.

Singular Health has been awarded a Kickstart 2 grant from Australia's peak science agency, CSIRO, matching \$50,000 of funding to conduct a project with CSIRO's Data61 division to automatically generate patient specific cranial implants for craniotomies from CT scans.

The Kickstart 2 grant follows Singular Health's highly successful Kickstart 1 project, which developed a spinal segmentation model with >95% accuracy (*ASX Announcement: Singular Health and CSIRO Successfully Deliver AI-Driven Spinal Segmentation Project 25 March 2021*) and will see Singular's technical team collaborate with Data61 to integrate the model into the 3Dicom Virtual Surgical Planning software.

Osteopore's collaboration with Singular Health will commence after the successful completion of the CSIRO Data61 project. The scope of the binding MOU is limited to the provision of a dataset of 40 craniotomy scans and existing cranial implants for validation of the AI-model with requisite ethics approvals for research and commercial usage; a \$10,000 contribution towards the collaboration in cash and in-kind; and the execution of formal collaboration documents within 60 days of executing the MOU, or as agreed by the parties.

The purpose of this six to twelve month collaboration is to conduct a comparative study to test and validate the accuracy and efficiency provided by the automated generation of patient specific cranial implant designs. The significance of this cooperative undertaking lies in the potentially significant design and process improvement opportunities afforded by Singular Health's AI technology and Osteopore looks forward to future collaborations and commercialisation prospects.

Osteopore's Chief Executive Officer, Khoon Seng Goh, commented:

"As a leader in regenerative medicine, Osteopore collaborates with a range of technologies that improve the efficacy of our regenerative implants. This win-win formula brings future technologies to commercialisation faster so that surgeons have new solutions for their treatment strategy, and patients can be treated early to make the most of their body's healing capacity."

Thomas Hanly, Singular Health's Chief Executive Officer, said:

"This project marks an exciting step for Singular Health as it highlights our expertise in Artificial Intelligence in the design of patient specific implants. Too often, advances in medical technology are made without the input of peers to focus on commercial priorities. Working with Osteopore ensures our work and results will be objectively compared with existing techniques and paves the way for future collaborations and commercialisation opportunities."

*This announcement has been approved for release by the Board of Osteopore.*

For more information, please contact:

**Carl Runde**

Chief Financial Officer

Osteopore Limited

+61 4 0011 8017

[carl\\_runde@osteopore.com](mailto:carl_runde@osteopore.com)

**About Osteopore Limited**

Osteopore Ltd, an Australian ASX listed company (OSX) with R&D and manufacturing in Singapore, is the global leader in the manufacture of innovative regenerative implants at commercial scale. By combining biomimetic tissue science with proprietary 3D printing and materials technology, Osteopore produces medical implants to meet the needs of both tissue and bone reconstruction as well as restoration. These bioresorbable implants provide a scaffold for bone regeneration, dissolving predictably over time to leave only natural bone tissue. In collaboration with clinicians and researchers, Osteopore develops and manufactures implants that address unmet clinical needs which improve patient outcomes, enhances lives, and potentially reduces healthcare costs. For more information, visit us at [www.osteopore.com](http://www.osteopore.com)

### **About Singular Health**

Founded in 2017, Singular Health is a medical technology company that has developed and commercialised the proprietary Volumetric Rendering Platform (“VRP”) for the 3D & VR visualisation of anatomy using standard radiological imagery.

Singular Health is committed to developing technologies that provides patients and practitioners alike with access to personalised, enhanced medical data to inform better health decisions and is currently developing and deploying software products that are built upon the proprietary VRP on a global scale through a direct-to-consumer Software-as-a-Service (“SaaS”) model.

### **About Scan to Surgery**

Scan to Surgery<sup>™</sup> is a disruptive technology driven process that revolutionises the planning and execution of surgical procedures, reducing cost and improving patient outcomes. Built on the backbone of MFTP, incorporating 3D/VR scan review with virtual surgical planning software and utilising local additive manufacturing facilities, Scan to Surgery<sup>™</sup> aims to rapidly deliver patient-specific solutions.

### **Forward Looking Statements**

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of Osteopore Limited, are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors.